A new therapy offers hopeful perspectives for patients suffering from spondyloarthropathy

Spondyloarthropathies are rheumatic infectious diseases affecting the spinal column and peripheral joints and tendons. These diseases either occur as such (Bechterew`s disease or ankylosing spondylitis), or are combined with skin psoriasis, inflammatory intestinal diseases (Crohn`s disease and ulcerating colitis), and eye infection (uveitis).

These diseases effect about 1% of total world population and often develop into seriously debilitating conditions with complete stiffening of the spinal column and destruction of the peripheral joints (hips, knees, wrists and/or fingers). Thus far, treatment of these diseases has been limited to the administration of non-steroid anti-inflammatory drugs, which may have a benevolent effect on the subjective complaints of pain, but does not effect the evolution of the disease.

Tumor Necrosis Factor is a small molecule (a cytokine) which is released by the disposal cells (macrophages) of the immune systems at sites where the inflammation occurs and which, in case of spondyloarthropathy, induces changes in the bone, joints and tendons.
Two years ago the Department of Rheumatology of the University of Ghent, Belgium, initiated an open study involving the treatment of 21 patients suffering from various forms of these diseases with intravenous injections of a monoclonal antibody targeting the Tumor Nacrosis Factor (Infliximab). The results were impressive not only with regard to the complaints, but also with regard to the symptoms of infection of the spinal column and the peripheral sites, and the infection factors measured in the blood. These results were confirmed in a double blind study involving 40 other patients, the data that were published in the March 6, 2002 issue of Arthritis and Rheumatology, the leading scientific journal in the area of rheumatology.

The conclusion of the study can be summarized as follows. The authors report the successful results of a double-blind placebo-controlled study with Infliximab on several sub-types of spondyloarthropathies. For the first time, we have an effective therapeutic option for severe cases. Long-term results (more than 1 year) of patients treated in the initial open study were already disclosed in a previous publication. The future of patients suffering from spondyloarthropathy is hopeful. It seems as if all requirements have been met to allow us to hope that this treatment will be able to prevent the stiffening of the spinal column and the destruction of the peripheral joints, and that the quality of life of these patients will improve considerably.

Media Contact

Eric VEYS alphagalileo

All latest news from the category: Health and Medicine

This subject area encompasses research and studies in the field of human medicine.

Among the wide-ranging list of topics covered here are anesthesiology, anatomy, surgery, human genetics, hygiene and environmental medicine, internal medicine, neurology, pharmacology, physiology, urology and dental medicine.

Back to home

Comments (0)

Write a comment

Newest articles

Pancreatic cancer’s cellular amnesia

Things aren’t always as they seem. Take pancreatic cancer, for example. In up to one in 10 cases, researchers have documented a peculiar characteristic. Some of the pancreatic cells appear…

Innovative Polymer Wound Dressings for Painless and Residue-Free Removal

A new approach enables dressings that adhere firmly to the skin at body temperature, but can be removed easily and painlessly in combination with a cold pack. The dressing adheres…

SETI Institute launches groundbreaking technosignature science and technology

Application deadline for grants is July 15, 2024. The SETI Institute is announcing the launch of a pioneering grants program dedicated to advancing technosignature science. This first-of-its-kind initiative aims to…

Partners & Sponsors